- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07942194
Prospective Multicentre Validation of a Landmark Machine Learning Model for ICU Mortality in Neurocritical Care (LANDMARK-ICU)
A Prospective Multicentre Observational Study Validating a Landmark-Based Machine Learning Model for Dynamic Prediction of Mortality in Patients Receiving Continuous Intracranial Pressure Monitoring
Mortality prediction in neurocritical care relies on scores computed at admission, which cannot update as the clinical course evolves. We previously developed a landmark-based machine learning model that converts hourly physiological data, including intracranial pressure, into an updating risk of death. The model was developed in a large public database and validated retrospectively in a second, independent one. This prospective multicentre study will test the model in consecutive patients at participating hospitals in Fujian Province, China. Physiological data will be collected as part of routine care. The model will generate risk estimates that are recorded for analysis but not shown to treating clinicians, and no treatment decision will be influenced by the study. The primary analysis will assess discrimination and calibration of the model for death during the intensive care stay. Secondary analyses will compare the model with severity scores in routine use and examine performance by aetiology.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Model development used the Medical Information Mart for Intensive Care IV database and external validation used the eICU Collaborative Research Database. Both analyses were retrospective and are not part of this registration. This registration covers the prospective multicentre validation only. Inclusion requires age 18 years or older, continuous intracranial pressure monitoring for at least 24 hours, and a diagnosis of traumatic brain injury, aneurysmal subarachnoid haemorrhage or intracerebral haemorrhage. The model uses seven hourly physiological channels with observation masks and elapsed-time features. The primary endpoint is death during the intensive care stay; 28-day mortality, length of stay and Glasgow Outcome Scale at 6 months are secondary. The sample size of 100 patients follows the approved protocol, which assumed area under the curve 0.80 with alpha 0.05 and beta 0.20.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Lieux d'étude
-
-
Fujian
-
Fuzhou, Fujian, Chine
- Fujian Provincial Hospital
-
Fuzhou, Fujian, Chine
- First Affiliated Hospital of Fujian Medical University
-
Quanzhou, Fujian, Chine
- Hui'an County Hospital
-
Quanzhou, Fujian, Chine
- Second Affiliated Hospital of Fujian Medical University
-
Quanzhou, Fujian, Chine
- Shishi City Hospital
-
Zhangzhou, Fujian, Chine
- Zhangzhou Municipal Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Adults in intensive care units of participating hospitals who require continuous intracranial pressure monitoring after acute brain injury.
La description
Inclusion Criteria:
- Age 18 years or older
- Continuous intracranial pressure monitoring for at least 24 hours
- Diagnosis of traumatic brain injury, aneurysmal subarachnoid haemorrhage or intracerebral haemorrhage
- Written informed consent from the patient or a legal representative
Exclusion Criteria:
- Incomplete or unusable intracranial pressure recordings
- Loss to follow-up or unavailable outcome information
- Pre-existing severe neurological disease that would confound assessment
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Neurocritical care cohort
Consecutive patients receiving continuous intracranial pressure monitoring, contributing to the risk set at each landmark. |
Observational application of a fixed prediction model to hourly physiological data; no treatment is assigned or withheld. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Area under the receiver operating characteristic curve (range 0 to 1) for death during the intensive care stay at the 24-hour landmark
Délai: 24 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28
|
Discrimination of the locked landmark model, quantified as the area under the receiver operating characteristic curve, where 0.5 indicates no discrimination and 1.0 perfect discrimination. Death is ascertained from the medical record and the curve is estimated with a 95% confidence interval |
24 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Area under the receiver operating characteristic curve (range 0 to 1) for death during the intensive care stay at the 48-hour and 72-hour landmarks
Délai: 48 and 72 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28
|
Same measurement as the primary outcome, estimated separately at the 48-hour and 72-hour landmarks with 95% confidence intervals |
48 and 72 hours after intensive care admission, with the outcome followed to intensive care unit discharge or day 28
|
|
Calibration slope (dimensionless) of the landmark model at the 24-, 48- and 72-hour landmarks
Délai: 24, 48 and 72 hours after intensive care admission
|
Slope obtained by logistic regression of the observed outcome on the logit of the predicted risk; a value of 1 indicates perfect calibration, below 1 indicates over-fitting and above 1 under-fitting. |
24, 48 and 72 hours after intensive care admission
|
|
Brier score (range 0 to 1) of the landmark model at the 24-, 48- and 72-hour landmarks
Délai: 24, 48 and 72 hours after intensive care admission
|
Mean squared difference between predicted risk and observed outcome, where lower values indicate better overall performance. |
24, 48 and 72 hours after intensive care admission
|
|
Difference in area under the receiver operating characteristic curve (range -1 to 1) between the landmark model and the centre-recorded APACHE II score
Délai: 24, 48 and 72 hours after intensive care admission
|
Paired difference in discrimination, computed as model area under the curve minus APACHE II area under the curve on the same patients, with 95% confidence interval; negative values indicate the model discriminates worse than APACHE II |
24, 48 and 72 hours after intensive care admission
|
|
Net benefit (dimensionless) of the landmark model from decision-curve analysis at the 24-hour landmark
Délai: 24 hours after intensive care admission
|
Net benefit computed across threshold probabilities from 0.05 to 0.50, compared with the strategies of treating all patients and treating none |
24 hours after intensive care admission
|
|
Area under the receiver operating characteristic curve (range 0 to 1) by primary diagnosis at the 24-, 48- and 72-hour landmarks
Délai: 24, 48 and 72 hours after intensive care admission
|
Discrimination estimated separately for traumatic brain injury, aneurysmal subarachnoid haemorrhage and intracerebral haemorrhage, reported descriptively because stratum sizes are expected to be small |
24, 48 and 72 hours after intensive care admission
|
|
28-day all-cause mortality, as specified in the approved protocol
Délai: 28 days after intensive care admission
|
28 days after intensive care admission
|
|
|
Length of intensive care stay
Délai: From intensive care admission to intensive care unit discharge, up to 28 days
|
Duration of intensive care stay in days, right-censored at day 28 for patients still in intensive care |
From intensive care admission to intensive care unit discharge, up to 28 days
|
|
Glasgow Outcome Scale score (range 1 to 5, higher is better) at 6 months
Délai: 6 months after intensive care admission
|
Glasgow Outcome Scale, an ordinal scale from 1 (death) to 5 (good recovery), with higher scores indicating better outcome; assessed by telephone or outpatient follow-up |
6 months after intensive care admission
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Han Chen, MD, Fujian Provincial Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Troubles cérébrovasculaires
- Maladies du cerveau
- Maladies du système nerveux central
- Maladies du système nerveux
- Maladies vasculaires
- Maladies cardiovasculaires
- Blessures et Blessures
- Processus pathologiques
- Attributs de la maladie
- Hémorragie
- Traumatisme crânio-cérébral
- Traumatisme, système nerveux
- Hémorragies intracrâniennes
- Lésions cérébrales
- Conditions pathologiques, signes et symptômes
- Lésions cérébrales, traumatiques
- Maladie critique
- Hémorragie cérébrale
- Hémorragie sous-arachnoïdienne
- Hypertension intracrânienne
Autres numéros d'identification d'étude
- FJPH-ICP-01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
De-identified individual participant data will not be shared publicly because small centre volumes could permit re-identification. The model specification, analysis code and summary results will be published.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .